Ascend to new heights
Clinical stage biotech company pioneering a novel class of ADCs
TPD²
Cell Selective Degradation
Our breakthrough protein degrader approach is designed to improve upon efficacy, safety, and half-life of conventional targeted protein degraders
Our pipeline will change the face of disease treatment
A portfolio of highly differentiated products combining the power of protein degraders with the precision of antibodies
Expanding the landscape of druggable targets, together
